Oncternal Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Encinatas CA United States (2013)

Organization Overview

First Clinical Trial
2016
NCT02657005
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Oncternal Therapeutics | Oncternal Therapeutics, Inc

Active Ingredients

Drugs in Phase 3 Trials (4)

Key: Oncternal Therapeutics (2) Acquired (2)

cirmtuzumab (2 trials)

enobosarm (12 trials)

ibrutinib (imbruvica) (1 trial)

toremifene (fareston) (4 trials)

Drugs in Phase 2 Trials (6)

Key: Oncternal Therapeutics (3) Acquired (3)

aav2/5 optirpe65 (2 trials)

gtx-758 (4 trials)

leuprolide (lupron) (1 trial)

onct-534 (1 trial)

onct-808 (1 trial)

venetoclax (venclexta) (1 trial)

Drugs in Phase 1 Trials (1)

tk216 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Neuroectodermal Tumors, Primitive, Peripheral (Phase 1)

Sarcoma (Phase 1)

Sarcoma, Ewing (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 27
  • # of Trial APIs: 11